Alirocumab: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:


==Properties==
==Properties==
Alirocumab is a human [[monoclonal antibody]] that binds proprotein convertase subtilisin/kexin type 9 ([[PCSK9]]). [[PCSK9]] is a protein that attaches to surface [[LDL]] receptors and triggers their degradation. This reduces the ability of hepatocytes to uptake LDL cholesterol and subsequently leads to increased levels of circulating LDL. By binding PCSK9, alirocumab inhibits LDL receptor destruction and increases the endocytosis of LDL from the circulation. Pre-clinical studies, and early clinical trials have shown the efficacy and safety of alirocumab in decreasing [[LDL]] [[cholesterol]] as an add-on agent or as monotherapy.


==Major Trials==
==Major Trials==

Revision as of 13:31, 19 March 2015

Pharmacologic interventions for PCSK9 Adapted from Journal of the American College of Cardiology, 62(16): 1401-1408[1]

For a review of all PCSK9 inhibitors please click here

WikiDoc Resources for Alirocumab

Articles

Most recent articles on Alirocumab

Most cited articles on Alirocumab

Review articles on Alirocumab

Articles on Alirocumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alirocumab

Images of Alirocumab

Photos of Alirocumab

Podcasts & MP3s on Alirocumab

Videos on Alirocumab

Evidence Based Medicine

Cochrane Collaboration on Alirocumab

Bandolier on Alirocumab

TRIP on Alirocumab

Clinical Trials

Ongoing Trials on Alirocumab at Clinical Trials.gov

Trial results on Alirocumab

Clinical Trials on Alirocumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alirocumab

NICE Guidance on Alirocumab

NHS PRODIGY Guidance

FDA on Alirocumab

CDC on Alirocumab

Books

Books on Alirocumab

News

Alirocumab in the news

Be alerted to news on Alirocumab

News trends on Alirocumab

Commentary

Blogs on Alirocumab

Definitions

Definitions of Alirocumab

Patient Resources / Community

Patient resources on Alirocumab

Discussion groups on Alirocumab

Patient Handouts on Alirocumab

Directions to Hospitals Treating Alirocumab

Risk calculators and risk factors for Alirocumab

Healthcare Provider Resources

Symptoms of Alirocumab

Causes & Risk Factors for Alirocumab

Diagnostic studies for Alirocumab

Treatment of Alirocumab

Continuing Medical Education (CME)

CME Programs on Alirocumab

International

Alirocumab en Espanol

Alirocumab en Francais

Business

Alirocumab in the Marketplace

Patents on Alirocumab

Experimental / Informatics

List of terms related to Alirocumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alirocumab (REGN727 and SAR236553) is an investigational human monoclonal antibody that inhibits PCSK9 for the treatment of hypercholesterolemia.

Properties

Alirocumab is a human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that attaches to surface LDL receptors and triggers their degradation. This reduces the ability of hepatocytes to uptake LDL cholesterol and subsequently leads to increased levels of circulating LDL. By binding PCSK9, alirocumab inhibits LDL receptor destruction and increases the endocytosis of LDL from the circulation. Pre-clinical studies, and early clinical trials have shown the efficacy and safety of alirocumab in decreasing LDL cholesterol as an add-on agent or as monotherapy.

Major Trials

Phase II Trials

Phase III Trials

References

  1. Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. (2013). "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis". J Am Coll Cardiol. 62 (16): 1401–8. doi:10.1016/j.jacc.2013.07.056. PMID 23973703. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources